-
Clinical Ophthalmology
-
About Dovepress
Open access peer-reviewed scientific and medical journals.
-
Open Access
Dove Medical Press is now a member of the Open Access Initiative
-
An Author's Guide
A guide to help authors get their paper published.
-
Advocacy
Support Open Access and Dove Press
-
Reprints
Promotional Article Monitoring - further details
-
Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Low-dose aspirin as treatment for central serous chorioretinopathy
Original Research
(4097) Views (1090) Full article downloads
Authors: Antonio Caccavale, Filippo Romanazzi, Manuela Imparato, et al
Published Date August 2010
Volume 2010:4 Pages 899 - 903
DOI: http://dx.doi.org/10.2147/OPTH.S12583
Antonio Caccavale1, Filippo Romanazzi1, Manuela Imparato1, Angelo Negri1, Anna Morano2, Fabio Ferentini11Department of Ophthalmology, Hospital C Cantù, Abbiategrasso, Milan; 2University Eye Clinic, Foundation IRCCS San Matteo Hospital, Pavia, Italy
Purpose: To evaluate the effectiveness of low-dose aspirin for the treatment of central serous chorioretinopathy (CSCR).
Patients and methods: Patients with classical or multifocal CSCR were treated with aspirin 100 mg per day orally for 1 month followed by 100 mg on alternate days for 5 months. Treated patients were compared with historic controls consisting of patients with classical or multifocal CSCR previously followed up at our institution.
Results: Mean visual acuity in the group treated with aspirin started to improve after the first week of therapy and continued to improve throughout the following 3 months. Visual recovery was slower in the untreated control group than in the treated group and achieved better visual acuity between the first and third month from the onset of the disease. There were no adverse events related to the administration of aspirin.
Conclusion: The results indicate that treatment with low-dose aspirin may result in more rapid visual rehabilitation with fewer recurrences in patient with CSCR compared with untreated historic controls. The effectiveness of treatment with aspirin supports our hypothesis regarding the role of impaired fibrinolysis and increased platelet aggregation in the choriocapillaris in the pathogenesis of CSCR.
Keywords: central serous chorioretinopathy, aspirin, plasminogen activator inhibitor 1, macula
Other articles by Dr Antonio Caccavale
Readers of this article also read:
Treatment of cystoid macular edema with the new-generation NSAID nepafenac 0.1%
Comparative studies of RNFL thickness measured by OCT with global index of visual fields in patients with ocular hypertension and early open angle glaucoma
Treatment of retinal pigment epithelial detachment with antiangiogenic therapy
Selective laser trabeculoplasty reduces mean IOP and IOP variation in normal tension glaucoma patients
Retinal nerve fiber layer evaluation in multiple sclerosis with spectral domain optical coherence tomography
Prevalence of retinopathy of prematurity in Latin America
Perfluorocarbon-perfused 23 gauge three-dimensional vitrectomy for complicated diabetic tractional retinal detachment
The use of amniotic membrane in trabeculectomy for the treatment of primary open-angle glaucoma: a prospective study
Pneumatic tools for vitreoretinal surgery
- Journal Indexing
See where all the Dove Press journals are indexed
- Interested in being a peer-reviewer?
Click here to register.
- Insight into 144 patients with ocular vascular events during VEGF antagonist injections
- Endophthalmitis: Pathogenesis, clinical presentation, management, and perspectives
- Protection of neurons in the retinal ganglion cell layer against excitotoxicity by the N-acylethanolamine, N-linoleoylethanolamine
- A computer-based anaglyphic system for the treatment of amblyopia




